Professor Sunghwa Choe is affiliated with Seoul National University, Korea. He received his Ph.D. degree in Plant Sciences and Biochemistry from the University of Arizona, USA, in 1997, and his Master’s degree in Biology in 1991 from Seoul National University, Korea. He founded a bioventure company, G+FLAS Life Sciences, in Korea and has been leading it as a Chief Executive Officer from the beginning. He has been a Visiting Professor at the University of Wisconsin Madison, USA, and Perdue University, USA. As a convergence specialist in a leading position, he served as the deputy director of the Advanced Institute of Convergence Technology, Korea, from 2012 to 2014, and director of the SNU & G Con Tech Academy, Korea, from 2014. Currently, he is active in the development of a more efficient CRISPR genome editing tool, its application for cancer therapy, the bioengineering of plants to obtain vitamin-D-fortified vegetables, humanized plants and the production of recombinant vaccines and antibodies for various diseases including COVID-19.
Professor Sunghwa Choe is affiliated with Seoul National University, Korea. He received his Ph.D. degree in Plant Sciences and Biochemistry from the University of Arizona, USA, in 1997, and his Master’s degree in Biology in 1991 from Seoul National University, Korea. He founded a bioventure company, G+FLAS Life Sciences, in Korea and has been leading it as a Chief Executive Officer from the beginning. He has been a Visiting Professor at the University of Wisconsin Madison, USA, and Perdue University, USA. As a convergence specialist in a leading position, he served as the deputy director of the Advanced Institute of Convergence Technology, Korea, from 2012 to 2014, and director of the SNU & G Con Tech Academy, Korea, from 2014. Currently, he is active in the development of a more efficient CRISPR genome editing tool, its application for cancer therapy, the bioengineering of plants to obtain vitamin-D-fortified vegetables, humanized plants and the production of recombinant vaccines and antibodies for various diseases including COVID-19.